The results of the present study demonstrated that andrographolide, a novel NF-κB inhibitor, inhibits the proliferation and invasion of NPC cells via suppressing NF-κB transcriptional activity and inhibiting the expression of NF-κB target genes. The gene discussed is NFKB1; the disease is nasopharyngeal carcinoma.